Checkpoint inhibitor/interleukin-based combination therapy of cancer

Background Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised in the area, as the recent studies showed that such therapeutic modality suffers from low durability and low or no efficacy for patients with some tumor types including cases with non-inflamed or cold cancers. Therefore, efforts have been made to solve the issue using immune combination therapy, such as the use of immunocytokines. The combination of ICI with interleukins (ILs) and IL-targeting agents is now under consideration in the area of therapy, and the primary results are promising. Purpose The focus of this review is to discuss the possibility of using ILs and IL-targeting drugs in combination with ICI in cancer immunotherapy and describing recent advances in the field using PEGylated ILs and fusion proteins. The key focus in this area is to reduce adverse events and to increase the efficacy and durability of such combination therapy.

Automated summary

This review discusses the potential of using ILs and IL-targeting drugs in combination with ICI in cancer immunotherapy, and describes recent advances in the field using PEGylated ILs and fusion proteins. The key focus in this area is to reduce adverse events and increase the efficacy and durability of combination therapy.